The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

In this article, we will take a look at the 12 stocks that will double in 2025.

The owner of the Los Angeles Times discusses his fight to cure cancer and why he wants President Donald Trump to succeed in ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

REPAY , a leading provider of vertically-integrated payment solutions, today announced a strategic integration with Worth, the all-in-one fintech platform for underwriting and onboarding workflow ...

The North American Veterinary Community (NAVC) named BestyBnB the 2025 NAVC Gives Marquee Award recipient, awarding the organization $25,000 for its work supporting the wellbeing of people and animals ...

January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA® (nogapendekin alfa inbakicept ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...